Back to User profile » Dr Hongrong Xu
Papers published by Dr Hongrong Xu:
Effect of Food on the Pharmacokinetics and Safety of a Novel c-Met Inhibitor SCC244: A Randomized Phase I Study in Healthy Subjects
Wu J, Xu H, Li H, Ma L, Chen J, Yuan F, Sheng L, Liu C, Chen W, Li X
Drug Design, Development and Therapy 2023, 17:761-769
Published Date: 10 March 2023
Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects
Sheng L, Cao W, Lin P, Chen W, Xu H, Zhong C, Yuan F, Chen H, Li H, Liu C, Yang M, Li X
Drug Design, Development and Therapy 2021, 15:1101-1110
Published Date: 9 March 2021
Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
Yang MJ, Xu HR, Li H, Chen WL, Yuan F, Li XN
Drug Design, Development and Therapy 2020, 14:1219-1226
Published Date: 24 March 2020
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
Liu C, Lu H, Yuan F, Chen WL, Xu HR, Li H, Hsu CP, Egbuna O, Wu J, Dias C, Abosaleem B, Rana J, Monsalvo ML, Li XN, Yu Z
Clinical Pharmacology: Advances and Applications 2019, 11:145-153
Published Date: 23 October 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
Xu HR, Sheng L, Chen WL, Yuan F, Yang MJ, Li H, Li XN, Choi J, Zhao GY, Hu TX, Li YG, Zhang Y, Chen L
Drug Design, Development and Therapy 2016, 10:1619-1626
Published Date: 9 May 2016